financetom
Business
financetom
/
Business
/
Aebi Schmidt Group Q4 Net Income, Revenue Rise; Issues 2026 Sales Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Aebi Schmidt Group Q4 Net Income, Revenue Rise; Issues 2026 Sales Guidance
Mar 19, 2026 4:43 AM

07:24 AM EDT, 03/19/2026 (MT Newswires) -- Aebi Schmidt Group (AEBI) on Thursday reported Q4 net income of $8.8 million, up from $6.1 million a year earlier.

Two analysts surveyed by FactSet expected $16.7 million.

Sales for the quarter ended Dec. 31 were $528.4 million, up from $499.7 million a year earlier.

An analyst polled by FactSet expected $528 million.

Aebi Schmidt ( AEBI ) said it expect 2026 sales of $1.95 billion to $2.15 billion. Three analysts polled by FactSet expected $2.05 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Biogen Begins Phase 3 Trial of Felzartamab for Rare Kidney Disease
Biogen Begins Phase 3 Trial of Felzartamab for Rare Kidney Disease
Jun 30, 2025
08:03 AM EDT, 06/30/2025 (MT Newswires) -- Biogen (BIIB) said Monday it initiated dosing in its global phase 3 trial to evaluate the investigational drug, felzartamab, in adults with primary membranous nephropathy, a severe autoimmune kidney disorder with no approved treatments. The company said the study will compare felzartamab to tacrolimus and enroll around 180 patients, with results expected in...
Avadel Faces Proxy Challenge Over Alleged Lumryz Launch 'Missteps'
Avadel Faces Proxy Challenge Over Alleged Lumryz Launch 'Missteps'
Jun 30, 2025
08:04 AM EDT, 06/30/2025 (MT Newswires) -- Avadel Pharmaceuticals ( AVDL ) is facing a proxy battle from ASL Strategic Value Fund, which urged shareholders Monday to vote against all company director nominees at the annual meeting scheduled for July 29. In an open letter, ASL accused Avadel's management of destroying significant shareholder value, citing alleged missteps with the launch...
S&P 500, Nasdaq Futures Rise Pre-Bell as Trade Optimism Grows
S&P 500, Nasdaq Futures Rise Pre-Bell as Trade Optimism Grows
Jun 30, 2025
08:04 AM EDT, 06/30/2025 (MT Newswires) -- S&P 500 and Nasdaq futures rose 0.4% and 0.6%, respectively, in Monday premarket activity as trade optimism increased after Canada scrapped a digital services tax in an effort to restart trade talks with the US. The S&P 500 and Nasdaq touched record highs in trading pre-bell Monday, according to multiple news reports. US...
Copyright 2023-2026 - www.financetom.com All Rights Reserved